Pneumocystis Pneumonia After Allogeneic Hematopoietic Cell Transplantation: A Case-Control Study on Epidemiology and Risk Factors on Behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

• Published in: Transplantation and cellular therapy 2024-02, Vol.30 (2), p.235.e1-235.e10
• Main Authors: Robin, Christine, Cordonnier, Catherine, Tridello, Gloria, Knelange, Nina, Xhaard, Alienor, Chantepie, Sylvain, Tanguy-Schmidt, Aline, Schouten, Harry C., Yeshurun, Moshe, Rocha, Vanderson, Srour, Micha, Kröger, Nicolaus, Ledoux, Marie-Pierre, Dalgaard, Jakob, Thiebaut, Anne, Giardino, Stefano, Calore, Elisabetta, Zuckerman, Tsila, Groll, Andreas H., Raida, Ludek, Avcin, Simona, Vicent, Marta Gonzalez, Kaare, Ain, Drozd-Sokolowska, Joanna, Turlure, Pascal, Bretagne, Stéphane, Mikulska, Malgorzata, Camara, Rafael de la, Cesaro, Simone, Styczynski, Jan
• Format: Article
• Language: English
• Subjects: Allogeneic HCT; Broncho-alveolar lavage; Pneumocystis jirovecii; Pneumocystosis; Quantitative polymerase chain reaction
• ISSN: 2666-6367; 2666-6367
• DOI: 10.1016/j.jtct.2023.11.017

Pneumocystis pneumonia (PCP) is a life-threatening complication after allogeneic hematopoietic cell transplantation (allo-HCT). However, allo-HCT procedures have evolved toward older patients, unrelated donors, and reduced-intensity conditioning, possibly modifying the risks. Polymerase chain reaction (PCR), widely used nowadays, is more sensitive than microscopy diagnostic methods. This study aimed to assess the factors associated with PCP in allo-HCT recipients within 2 years of HCT and managed according to current procedures. This multicenter, nested case-control study included PCP cases diagnosed by PCR, cytology, or immunofluorescence on bronchoalveolar lavage fluid between 2016 and 2018. Two controls per case were selected from the ProMISe registry and matched for the center, transplant date, and underlying disease. Fifty-two cases and 104 controls were included among the 5452 patients who underwent allo-HCT in the participating centers. PCP occurred at a median of 11.5 months after transplantation. The mortality rate was 24% on day 30 after the PCP diagnosis and 37% on day 90. The clinical presentation and mortality rates of the 24 patients diagnosed using only PCR were not different from those diagnosed with microscopy methods. Our study demonstrates a substantial incidence of, and mortality from, PCP, after allogeneic HCT despite well-established prophylactic approaches. In our experience, PCP nowadays occurs later after transplant than previously reported, justifying the prolongation of prophylaxis after six months in many cases. Allo-HCT recipients diagnosed with PCR as the only PCP marker should benefit from specific treatment as for other patients.